TRAX — First Tracks Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2091349 ·
Last close
$43.57
Market Cap
$1.83B
52W High
$54.78
52W Low
$14.72
ADV30
984,432
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -32,844,000 | -31,356,000 | 170,456,000 | 155,627,000 | 19,445,000 |
| Jun 2026 | 0 | — | -34,937,000 | -33,374,000 | 183,140,000 | 168,018,000 | 14,344,000 |
| Mar 2026 | 0 | — | -52,811,000 | -50,484,000 | 290,576,000 | 248,469,000 | 33,112,000 |
| Sep 2025 | 0 | — | -45,057,000 | -41,859,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-112,221,000
Investing CF
$138,240,000
Financing CF
$-43,053,000
CapEx
$-93,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.49
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-55,932,000
Inventory
—
Receivables
$2,869,000
ST Investments
$0
EBIT TTM
$-165,649,000
Pretax Income TTM
$-157,073,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 0 | -181,101,000 | -163,705,000 | 441,891,000 | 50,295,000 | 391,596,000 | -125,806,000 |
| Dec 2023 | 0 | -118,461,000 | -106,150,000 | 444,109,000 | 34,260,000 | 409,849,000 | -93,004,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$183,140,000
Forward EPS
$-3.51
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $44.50 · call volume: 104 · put volume: 8
Expected Move to 2027-04-16:
±$18.90
(42.47%) —
implied range
$25.60 –
$63.40
· ATM straddle on $45.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ETON | Eton Pharmaceuticals, Inc. | $1.84B | $63.65 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.79B | $29.89 | — |
| HMDCF | HUTCHMED (China) Ltd | $1.88B | $2.16 | — |
| ZYME | Zymeworks Inc. | $1.78B | $25.84 | — |
| ZBIO | Zenas BioPharma, Inc. | $1.88B | $27.75 | — |
News headlines (Yahoo Finance, 1h cache)
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
2026-11-03 21:15 · Yahoo
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-03 21:15 · Yahoo
First Tracks Biotherapeutics Announces $200 Million Private Placement
2026-10-15 12:00 · Yahoo
7 Reasons First Tracks Biotherapeutics (TRAX) Looks Pricey Following ANB033 Trial Data
2026-10-13 12:18 · Yahoo
First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data
2026-10-13 11:16 · Yahoo
First Tracks Biotherapeutics (TRAX) Reports Positive Phase 1b Cohort 1 Results
2026-10-13 10:12 · Yahoo
First Tracks climbs on ‘impressive’ celiac study data
2026-10-12 21:26 · Yahoo
Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
2026-10-12 20:10 · Yahoo
First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals
2026-10-12 17:02 · Yahoo
First Tracks Biotherapeutics Shares Jump 20% After Positive Phase 1b Celiac Disease Trial Results
2026-10-12 12:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.